Document is current
Any future updates will be listed below
-
Authors
Schauer, Tim https://orcid.org/0000-0002-0717-3954
Henriksson, Anna https://orcid.org/0000-0002-2631-7757
Strandberg, Emelie https://orcid.org/0000-0001-5549-8326
Lindman, Henrik https://orcid.org/0000-0002-2068-4708
Berntsen, Sveinung
Demmelmaier, Ingrid
Raastad, Truls https://orcid.org/0000-0002-2567-3004
Nordin, Karin https://orcid.org/0000-0001-8685-3722
Christensen, Jesper F. https://orcid.org/0000-0003-4858-1505
-
Funding
Funding for this research was provided by:
The Swedish Cancer Society (150841, 160483)
The Swedish Research Council (KDB/9514)
The Nordic Cancer Union (2015)
The Oncology Department Foundations Reseach Fund in Uppsala (2016, 2017)
Trygfonden (101390, 20045)
Lundbeckfonden
Wereld Kanker Onderzoek Fonds (IIG_2016_1635)
- License Information
-
More Information
Article History
Received: 18 May 2022
Accepted: 9 October 2022
First Online: 21 October 2022
Declarations
:
: HL received research funding by Roche and honoraria from Astra-Zeneca and Eli Lilly and Company in the form of lecture and consultation fees. All other authors have no relevant financial or non-financial interests to disclose. None of the entities providing funds had any role in study design, analysis, manuscript writing or decision to submit for publication.
: This study was performed in line with the principles of the Declaration of Helsinki and its later amendments. Approval was granted by the Swedish Ethical Review Authority (Dnr 2014/249).
: Informed consent was obtained from all individual participants included in the study.
